PTC Therapeutics | PTCT - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12
Xencor USD -53.63M 6.11M 2025-12